Peritech Pharma

Company Overview

Snapshot

Founded in March 2012 by Eran Eilat, Peritech Pharma operates with 1–10 employees. The company holds one patent and has secured one funding round from one investor. In February 2018, Peritech Pharma commercialized its novel hemorrhoids treatment in 24 countries.

Business overview

Peritech Pharma is a specialty pharmaceuticals development company focused on products for the anal/rectal area. The company's core products, PP-110 for hemorrhoids and PP-120 for anal itching, are based on known and approved active ingredients and feature a delivery mechanism designed for long-lasting effects. Peritech Pharma serves the pharmaceutical and healthcare markets, operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.

Strategic signal

In February 2018, Peritech Pharma announced the commercialization of its novel hemorrhoids treatment in 24 countries, following a commercial agreement with Latam BD Group. This expansion into Central and South America, as well as the Caribbean, signals significant market validation and a strategic move to broaden the reach of its over-the-counter products, PP-110 and PP-120, indicating strong commercial momentum for its specialized pharmaceutical solutions.

Company Intelligence Q&A

What is Peritech Pharma's primary focus?

Peritech Pharma specializes in developing specialty pharmaceutical products for the anal and rectal area, including treatments for hemorrhoids and anal itching.

When was Peritech Pharma founded and by whom?

Peritech Pharma was founded in March 2012 by Eran Eilat.

What was a key commercial milestone for Peritech Pharma?

In February 2018, Peritech Pharma commercialized its novel hemorrhoids treatment in 24 countries through a deal with Latam BD Group, covering markets in Central and South America and the Caribbean.

Has Peritech Pharma been granted any patents?

In May 2019, Peritech Pharma was granted patents for its products in China and Russia.

What clinical evidence supports Peritech Pharma's hemorrhoids treatment?

In July 2015, clinical trials demonstrated that Peritech Pharma's novel hemorrhoids treatment, PP-110, was superior to Preparation-H, with participants reporting better results for pain, itching, and bleeding when using PP-110 once daily compared to other comparable drugs used more frequently.